Literature DB >> 66984

In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine.

R L Momparler, J Goodman.   

Abstract

The in vitro effect of 5-aza-2'-deoxycytidine (5-aza-CdR) on cytotoxicity and macromolecular synthesis in A(T1)C1-3 hamster fibrosarcoma cells was investigated. The in vitro concentrations that produce 50% cell kill for 5-aza-CdR were about 1.0 and 0.01 microng/ml for a 2- and 24-hr exposure, respectively. 5-aza-CdR inhibited the growth of the fibrosarcoma cells by 40% at a concentration of 0.05 microng/ml. Deoxycytidine, but not cytidine, was a potent antagonist of the cytotoxicity produced by 5-aza-CdR. At cytotoxic concentrations 5-aza-CdR did not appear to inhibit DNA, RNA, or protein synthesis during a 1-hr incubation as measured by the incorporation of radioactive thymidine, uridine,, or leucine into acid-insoluble material. At a concentration of 10 microng/ml, 5-aza-CdR stimulated the incorporation of radioactive thymidine into DNA by more than 50%. These results indicate that 5-aza-CdR is a very potent cytotoxic agent to tumor cells in vitro at concentrations that do not inhibit macromolecular synthesis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66984

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.

Authors:  G Schwartsmann; H Schunemann; C N Gorini; A F Filho; C Garbino; G Sabini; I Muse; L DiLeone; D R Mans
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.

Authors:  Santosh Saraf; Hiroto Araki; Benjamin Petro; Youngmin Park; Simona Taioli; Kazumi G Yoshinaga; Emre Koca; Damiano Rondelli; Nadim Mahmud
Journal:  Transfusion       Date:  2014-11-02       Impact factor: 3.157

4.  Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Authors:  Jean-Pierre J Issa; Gail Roboz; David Rizzieri; Elias Jabbour; Wendy Stock; Casey O'Connell; Karen Yee; Raoul Tibes; Elizabeth A Griffiths; Katherine Walsh; Naval Daver; Woonbok Chung; Sue Naim; Pietro Taverna; Aram Oganesian; Yong Hao; James N Lowder; Mohammad Azab; Hagop Kantarjian
Journal:  Lancet Oncol       Date:  2015-08-19       Impact factor: 41.316

Review 5.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

6.  Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.

Authors:  Pramod Terse; Kory Engelke; Kenneth Chan; Yonghua Ling; Douglas Sharpnack; Yogen Saunthararajah; Joseph M Covey
Journal:  Int J Toxicol       Date:  2014-03-17       Impact factor: 2.032

7.  3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.

Authors:  W J Moriconi; M Slavik; S Taylor
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

Authors:  K P Ng; Q Ebrahem; S Negrotto; R Z Mahfouz; K A Link; Z Hu; X Gu; A Advani; M Kalaycio; R Sobecks; M Sekeres; E Copelan; T Radivoyevitch; J Maciejewski; J C Mulloy; Y Saunthararajah
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

9.  Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].

Authors:  B J Braakhuis; G A van Dongen; M van Walsum; A Leyva; G B Snow
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

10.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.